Cargando…
The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial
BACKGROUND: Sodium bicarbonate (SB) has been proposed as an ergogenic aid, as it improves high-intensity and resistance exercise performance. However, no studies have yet investigated SB application in CrossFit. This study examined the effects of chronic, progressive-dose SB ingestion on CrossFit-li...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957406/ https://www.ncbi.nlm.nih.gov/pubmed/29771966 http://dx.doi.org/10.1371/journal.pone.0197480 |
_version_ | 1783324058376470528 |
---|---|
author | Durkalec-Michalski, Krzysztof Zawieja, Emilia E. Podgórski, Tomasz Łoniewski, Igor Zawieja, Bogna E. Warzybok, Marta Jeszka, Jan |
author_facet | Durkalec-Michalski, Krzysztof Zawieja, Emilia E. Podgórski, Tomasz Łoniewski, Igor Zawieja, Bogna E. Warzybok, Marta Jeszka, Jan |
author_sort | Durkalec-Michalski, Krzysztof |
collection | PubMed |
description | BACKGROUND: Sodium bicarbonate (SB) has been proposed as an ergogenic aid, as it improves high-intensity and resistance exercise performance. However, no studies have yet investigated SB application in CrossFit. This study examined the effects of chronic, progressive-dose SB ingestion on CrossFit-like performance and aerobic capacity. METHODS: In a randomized, double-blind, cross-over trial, 21 CrossFit-trained participants were randomly allocated to 2 groups and underwent 2 trials separated by a 14-day washout period. Participants ingested either up to 150 mg∙kg(-1) of SB in a progressive-dose regimen or placebo for 10 days. Before and after each trial, Fight Gone Bad (FGB) and incremental cycling (ICT) tests were performed. In order to examine biochemical responses, blood samples were obtained prior to and 3 min after completing each exercise test. RESULTS: No gastrointestinal (GI) side effects were reported during the entire protocol. The overall FGB performance improved under SB by ~6.1% (p<0.001) and it was ~3.1% higher compared to post placebo (PLA(post)) (p = 0.040). The number of repetitions completed in each round also improved under SB (mean from baseline: +5.8% to +6.4%). Moreover, in ICT, the time to ventilatory threshold (VT) (~8:25 min SB(post) vs. ~8:00 min PLA(post), p = 0.020), workload at VT (~218 W SB(post) vs. ~208 W PLA(post), p = 0.037) and heart rate at VT (~165 bpm SB(post) vs. ~161 bpm PLA(post), p = 0.030) showed higher SB(post) than PLA(post). Furthermore, the maximum carbon dioxide production increased under SB by ~4.8% (from ~3604 mL∙min(-1) to ~3776 mL∙min(-1), p = 0.049). Pyruvate concentration and creatine kinase activity before ICT showed higher SB(post) than PLA(post) (~0.32 mmol∙L(-1) vs. ~0.26 mmol∙L(-1), p = 0.001; ~275 U∙L(-1) vs. ~250 U∙L(-1), p = 0.010, respectively). However, the small sample size limits the wide-application of our results. CONCLUSIONS: Progressive-dose SB ingestion regimen eliminated GI side effects and improved CrossFit-like performance, as well as delayed ventilatory threshold occurrence. |
format | Online Article Text |
id | pubmed-5957406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-59574062018-05-31 The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial Durkalec-Michalski, Krzysztof Zawieja, Emilia E. Podgórski, Tomasz Łoniewski, Igor Zawieja, Bogna E. Warzybok, Marta Jeszka, Jan PLoS One Research Article BACKGROUND: Sodium bicarbonate (SB) has been proposed as an ergogenic aid, as it improves high-intensity and resistance exercise performance. However, no studies have yet investigated SB application in CrossFit. This study examined the effects of chronic, progressive-dose SB ingestion on CrossFit-like performance and aerobic capacity. METHODS: In a randomized, double-blind, cross-over trial, 21 CrossFit-trained participants were randomly allocated to 2 groups and underwent 2 trials separated by a 14-day washout period. Participants ingested either up to 150 mg∙kg(-1) of SB in a progressive-dose regimen or placebo for 10 days. Before and after each trial, Fight Gone Bad (FGB) and incremental cycling (ICT) tests were performed. In order to examine biochemical responses, blood samples were obtained prior to and 3 min after completing each exercise test. RESULTS: No gastrointestinal (GI) side effects were reported during the entire protocol. The overall FGB performance improved under SB by ~6.1% (p<0.001) and it was ~3.1% higher compared to post placebo (PLA(post)) (p = 0.040). The number of repetitions completed in each round also improved under SB (mean from baseline: +5.8% to +6.4%). Moreover, in ICT, the time to ventilatory threshold (VT) (~8:25 min SB(post) vs. ~8:00 min PLA(post), p = 0.020), workload at VT (~218 W SB(post) vs. ~208 W PLA(post), p = 0.037) and heart rate at VT (~165 bpm SB(post) vs. ~161 bpm PLA(post), p = 0.030) showed higher SB(post) than PLA(post). Furthermore, the maximum carbon dioxide production increased under SB by ~4.8% (from ~3604 mL∙min(-1) to ~3776 mL∙min(-1), p = 0.049). Pyruvate concentration and creatine kinase activity before ICT showed higher SB(post) than PLA(post) (~0.32 mmol∙L(-1) vs. ~0.26 mmol∙L(-1), p = 0.001; ~275 U∙L(-1) vs. ~250 U∙L(-1), p = 0.010, respectively). However, the small sample size limits the wide-application of our results. CONCLUSIONS: Progressive-dose SB ingestion regimen eliminated GI side effects and improved CrossFit-like performance, as well as delayed ventilatory threshold occurrence. Public Library of Science 2018-05-17 /pmc/articles/PMC5957406/ /pubmed/29771966 http://dx.doi.org/10.1371/journal.pone.0197480 Text en © 2018 Durkalec-Michalski et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Durkalec-Michalski, Krzysztof Zawieja, Emilia E. Podgórski, Tomasz Łoniewski, Igor Zawieja, Bogna E. Warzybok, Marta Jeszka, Jan The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial |
title | The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial |
title_full | The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial |
title_fullStr | The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial |
title_full_unstemmed | The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial |
title_short | The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial |
title_sort | effect of chronic progressive-dose sodium bicarbonate ingestion on crossfit-like performance: a double-blind, randomized cross-over trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957406/ https://www.ncbi.nlm.nih.gov/pubmed/29771966 http://dx.doi.org/10.1371/journal.pone.0197480 |
work_keys_str_mv | AT durkalecmichalskikrzysztof theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT zawiejaemiliae theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT podgorskitomasz theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT łoniewskiigor theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT zawiejabognae theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT warzybokmarta theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT jeszkajan theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT durkalecmichalskikrzysztof effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT zawiejaemiliae effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT podgorskitomasz effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT łoniewskiigor effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT zawiejabognae effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT warzybokmarta effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial AT jeszkajan effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial |